Farnesyltransferase inhibitor

Revision as of 02:36, 9 August 2012 by WikiBot (talk | contribs) (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Farnesyltransferase inhibitor

Articles

Most recent articles on Farnesyltransferase inhibitor

Most cited articles on Farnesyltransferase inhibitor

Review articles on Farnesyltransferase inhibitor

Articles on Farnesyltransferase inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Farnesyltransferase inhibitor

Images of Farnesyltransferase inhibitor

Photos of Farnesyltransferase inhibitor

Podcasts & MP3s on Farnesyltransferase inhibitor

Videos on Farnesyltransferase inhibitor

Evidence Based Medicine

Cochrane Collaboration on Farnesyltransferase inhibitor

Bandolier on Farnesyltransferase inhibitor

TRIP on Farnesyltransferase inhibitor

Clinical Trials

Ongoing Trials on Farnesyltransferase inhibitor at Clinical Trials.gov

Trial results on Farnesyltransferase inhibitor

Clinical Trials on Farnesyltransferase inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Farnesyltransferase inhibitor

NICE Guidance on Farnesyltransferase inhibitor

NHS PRODIGY Guidance

FDA on Farnesyltransferase inhibitor

CDC on Farnesyltransferase inhibitor

Books

Books on Farnesyltransferase inhibitor

News

Farnesyltransferase inhibitor in the news

Be alerted to news on Farnesyltransferase inhibitor

News trends on Farnesyltransferase inhibitor

Commentary

Blogs on Farnesyltransferase inhibitor

Definitions

Definitions of Farnesyltransferase inhibitor

Patient Resources / Community

Patient resources on Farnesyltransferase inhibitor

Discussion groups on Farnesyltransferase inhibitor

Patient Handouts on Farnesyltransferase inhibitor

Directions to Hospitals Treating Farnesyltransferase inhibitor

Risk calculators and risk factors for Farnesyltransferase inhibitor

Healthcare Provider Resources

Symptoms of Farnesyltransferase inhibitor

Causes & Risk Factors for Farnesyltransferase inhibitor

Diagnostic studies for Farnesyltransferase inhibitor

Treatment of Farnesyltransferase inhibitor

Continuing Medical Education (CME)

CME Programs on Farnesyltransferase inhibitor

International

Farnesyltransferase inhibitor en Espanol

Farnesyltransferase inhibitor en Francais

Business

Farnesyltransferase inhibitor in the Marketplace

Patents on Farnesyltransferase inhibitor

Experimental / Informatics

List of terms related to Farnesyltransferase inhibitor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


The farnesyltransferase inhibitors (FTIs) are a class of experimental cancer drugs that target protein farnesyltransferase with the downstream effect of preventing the proper functioning of the Ras protein, which is commonly abnormally active in cancer.

Background

Studies have suggested that interference with certain post-translational modification processes seem to have quite a high selectivity for targeting cells displaying tumour phenotypes although the reason for this is a matter of controversy (as will be explained below).

After translation, RAS goes through four steps of modification: isoprenylation, proteolysis, methylation and palmitoylation. Isoprenylation involves the enzyme farnesyltransferase (FTase) transferring a farnesyl group from farnesyl pyrophosphate (FPP) to the pre-RAS protein. Also, a related enzyme geranylgeranyltransferase I (GGTase I) has the ability to transfer a geranylgeranyl group to K and N-RAS (the implications of this are discussed below). Farnesyl is necessary to attach RAS to the cell membrane. Without attachment to the cell membrane, RAS is not able to transfer signals from membrane receptors (Reuter et al., 2000).

Development of FTIs

After a program of high-throughput screening of a class of drugs targeting the first step, the farnesyltransferase inhibitors (FTIs) were developed (Reuter et al., 2000). A number of molecules were found to have FTI activity. Some earlier compounds were found to have major side effects, and their development was discontinued. The others have entered clinical trials for different cancers. SCH66336 (Lonafarnib) was the first to do so, followed by R115777 (Zarnestra, Tipifarnib) (Caponigro et al., 2003).

Unfortunately, the predicted “early potential [of FTIs] has not been realised” (Downward J, 2003). The anti-tumour properties of FTIs were attributed to their action on RAS processing; however this assumption has now been questioned. Of the three members (H, N and K) of the RAS family, K-RAS is the form found most often mutated in cancer. As noted above, as well as modification by FFTase an alternative route to creation of biologically active RAS is through GGTase modification. When FFTase is blocked by FFTase inhibitors this pathway comes in to operation – both K and N-RAS are able to be activated through this mechanism. In recognition of this a joint administration of FTIs and GTIs was tried, however this resulted in high toxicity. It is in fact thought that the lack of FTI toxicity may be due to a failure to fully inhibit RAS: FTIs actually target normal cells but alternative pathway allow these cells to surive (Downward J, 2003).

Explaining success

So how to explain the preclinical successes showing that many N- or K-RAS transformed cell lines (and even tumor cell lines that do not harbor RAS mutations) are sensitive to FTase inhibitors? It has been suggested that this is due to inhibition of farnesylation of a number of other proteins (Reuter et al., 2000). Therefore it is hoped that FTIs, whilst not RAS specific, still have potential for cancer therapy.

Products in Development

Tipifarnib
Lonafarnib

Investigation of FTIs for alternative uses

FTIs and protozoan parasites

FTIs can also be used to inhibit farnesylation in parasites such as Trypanosoma brucei (African sleeping sickness) and Plasmodium falciparum (malaria). Interestingly, these parasites seem to be more vulnerable to inhibition of Farnesyltransferase than humans, even though the drugs tested selectively target human FTase. In some cases the reason for this may be the parasites lack Geranylgeranyltransferase I. This vulnerability may pave the way for the development of selective, low toxicity, FTI based anti-parasitic drugs 'piggybacking' on the development of FTIs for cancer research.

Use with Progeria

Recently studies have been published indicating that farnesyltransferase inhibitors can act to reverse instability of nuclear structure due to the genetic mutation of the LMNA gene. It is being tested as a potential drug treatment in children suffering from Hutchinson-Gilford Progeria Syndrome.

References



Template:WikiDoc Sources